Gene-Editing Transfection Chemicals Market Report 2025

The gene-editing transfection chemicals market size has grown strongly in recent years. It will grow from $0.99 billion in 2024 to $1.07 billion in 2025 at a compound annual growth rate (CAGR) of 8%. The expansion during the historic period was driven by the early implementation of CRISPR-Cas9 technology, increased emphasis on cancer and genetic disorder studies, initial demand from academic and research organizations, the accessibility of fundamental chemical transfection reagents, and the swift advancement of cell biology and molecular diagnostics.

The gene-editing transfection chemicals market size is expected to see strong growth in the next few years. It will grow to $1.45 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The projected growth during the forecast period is driven by the expanding application of gene editing in clinical therapies, increased investments from biotech and pharmaceutical sectors, rising demand for non-viral delivery methods, growing incidence of rare and inherited diseases, worldwide focus on personalized medicine, and the advancement of regenerative treatments. Key trends expected to shape this period include a move toward nanoparticle and lipid-based delivery systems, the adoption of automation and high-throughput technologies, the rise of microfluidic and single-cell delivery techniques, integration of nanotechnology, and the development of core-shell silica nanoparticle platforms.

The accelerated research in gene therapy is anticipated to drive the growth of the gene-editing transfection chemicals market in the coming years. Gene therapy is a technique aimed at treating or preventing diseases by directly modifying or correcting defective genes within an individual's cells. Progress in gene therapy is speeding up due to breakthroughs in gene-editing technologies like CRISPR, which allow scientists to accurately target and alter faulty genes responsible for genetic disorders. Gene-editing transfection chemicals play a crucial role in gene therapy research and development by enabling the efficient delivery of genetic materials such as CRISPR-Cas9 components, mRNA, and plasmid DNA into human cells. For example, in August 2024, PartnerRe, a Switzerland-based insurance company, reported that by the end of 2023, the FDA had approved 7 gene therapies, with 2024 expected to set a new record by approving seven more within the first half of the year. Currently, over 500 gene therapies are in development, and the FDA is projected to approve an additional 10 to 20 gene and cell therapies by 2025. Consequently, the rapid advancements in gene therapy are fueling the expansion of the gene-editing transfection chemicals market.

Leading companies in the gene-editing transfection chemicals market are concentrating on launching innovative solutions, such as lipid nanoparticle (LNP) starter kits, to simplify gene therapy and mRNA delivery processes. Lipid nanoparticle (LNP) starter kits are ready-to-use formulations or toolkits that include pre-optimized lipid components and protocols designed to aid in the development and testing of LNP-based delivery systems. For instance, in February 2024, CordenPharma, a Switzerland-based pharmaceutical firm, introduced Lipid NanoParticle (LNP) Starter Kits intended to assist researchers and developers in formulating and optimizing mRNA-based therapeutics, including vaccines and gene therapies. These kits feature four essential lipids - ionizable lipids, helper lipids, sterols, and PEGylated lipids - sourced from commercial-scale, high-purity materials to ensure consistency between batches and minimize the risk of losing valuable payloads during development. By offering a dependable and scalable lipid platform, CordenPharma aims to speed up the development of gene editing and mRNA therapeutics while protecting high-value genetic payloads.

In August 2024, Merck KGaA, a Germany-based science and technology company, acquired Mirus Bio LLC for $600 million. Through this acquisition, Merck seeks to enhance its goal of providing fully integrated and comprehensive solutions for all stages of viral vector manufacturing, supporting the development and commercialization of cell and gene therapies from preclinical research through to commercial production. Mirus Bio LLC, based in the US, produces transfection reagents used in gene editing and other cell and gene therapy applications.

Major players in the gene‑editing transfection chemicals market are Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies Inc., Lonza Group AG, Sartorius AG, Bio-Rad Laboratories Inc., Takara Bio Inc., GenScript Biotech Corporation, Integrated DNA Technologies Inc., Promega Corporation, Eurogentec S.A., Horizon Discovery Group plc, OriGene Technologies Inc., Enzo Life Sciences Inc., Apollo Scientific Ltd., Mirus Bio LLC, OZ Biosciences SAS, Genlantis Inc., Polyplus-Transfection SA, Altogen Biosystems LLC, Canvax Biotech S.L., EZ Biosystems LLC, and SignaGen Laboratories.

North America was the largest region in the gene‑editing transfection chemicals market in 2024. The regions covered in gene-editing transfection chemicals report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the gene-editing transfection chemicals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gene-editing transfection chemicals market consists of sales of products, including lipid-based transfection reagents, polymer-based transfection reagents, electroporation buffers and kits, nanoparticle-based delivery systems, and cell-specific transfection reagents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The gene-editing transfection chemicals market research report is one of a series of new reports that provides gene-editing transfection chemicals market statistics, including gene-editing transfection chemicals industry global market size, regional shares, competitors with a gene-editing transfection chemicals market share, detailed gene-editing transfection chemicals market segments, market trends and opportunities, and any further data you may need to thrive in the gene-editing transfection chemicals industry. This gene-editing transfection chemicals market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gene-editing transfection chemicals are specially designed substances that enable the efficient transfer of gene-editing tools like CRISPR-Cas9 complexes, plasmid DNA, or RNA molecules into living cells by helping them cross the cell membrane intact. These agents are vital for achieving high transfection efficiency and successful genome editing because they safeguard the genetic material and support its uptake, expression, and function within the target cells.

The primary types of gene-editing transfection chemicals include lipid-based, polymer-based, peptide-based, and others. Lipid-based transfection agents consist of lipid molecules that assist in delivering gene-editing tools such as CRISPR-Cas9 into cells. These chemicals use various delivery strategies, including both viral and non-viral methods, and have applications across biomedical research, drug discovery, disease modeling, agricultural biotechnology, vaccine development, and more. Their main users are academic and research institutions, biotechnology firms, pharmaceutical companies, and others.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.